News

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

A Biden presidency will mean the immediate expansion of health insurance coverage and perhaps a public option. A second term for President Trump would mean renewed efforts to repeal and replace the ACA and emphasis on consumer choice.

In this episode of Tuning Into the C-Suite, listeners are tuning into our next feature of the Meet the Board series where MHE's Senior Editor, Peter Wehrwein, and Associate Editor, Briana Contreras, speak with Managed Healthcare Executive Editorial Advisory Board Member, Don Hall, who is principal of DeltaSigma LLC. DeltaSigma is a consulting practice specializing in strategic problem solving for managed care organizations. In addition to being a loyal member of our board since 2007, Don most recently served as president and CEO of a nonprofit, provider-sponsored health plan. In this conversation, you’ll learn a bit about Don, personally, such as what he's currently reading, and his thoughts about the current issues healthcare is facing today.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

According to a new survey provided by the American Psychological Association (APA), more than 68% of U.S. adults say the 2020 U.S. presidential election is a significant source of stress in their life. The APA offers advice on how to handle election stress.

Pfizer, the reputed leader in the COVID-19 vaccine race, may not have efficacy results for awhile. Meanwhile, AstraZeneca and Johnson & Johnson have resuming enrolling volunteers in the U.S. in their late-stage trials.

The treatment is a combination of ublituximab, its investigational glycoengineered anti-CD20 monoclonal antibody, and umbralisib, the company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon.

Medical company secures Investigational New Drug Application from FDA for its gummy medication.

Healthcare HR professionals—if they haven’t already—must reshape the workplace each and every day by focusing intently and with new eyes on what matters most during this ongoing pandemic: employees.

As payer and provider organizations look to improve health outcomes around the far-reaching impacts of the pandemic, they must consider the unique needs of some of our most vulnerable populations, such as new and expecting mothers and their infants.

In the consolidated PBM industry, smaller companies say they can be nimble and not driven by rebates. But are they acquisition targets?

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a Q&A interview between MHE and the emerging leader.

People with MS who are at risk for joblessness have poorer health-related habits and lower “locus of control” scores, according to findings by Kessler Foundation researcher Lauren Strober.

Gilead's Veklury gets full approval; AstraZeneca's Tagrisso heads toward second indication in NSCLC; another use for experimental antifungal therapy.

Quality impacts health outcomes. But do in-person quality measures meaningfully translate to telemedicine? Do the same measures that predict a doctor’s ability to deliver excellent in-person care also predict if s/he is a good “virtualist?”

The legislation follows an investigation that highlighted how minorities experience much higher rates of lower limb amputation than whites.

Study found that while frequency of cancer among people with multiple sclerosis (MS) increased over time, the overall cancer risk is similar between patients with MS and the general population.

The more we rely on technology, the further away we get from focusing on and addressing one of the most critical components of care: Trust between the patient and doctor.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a Q&A interview between MHE and the emerging leader.

Suppliers of personal protective equipment have come up with innovative ways to meet the demand, but one expert notes the lack of rigorous research into its efficacy.

“Lung cancer screening is a great example of the problem,” says the former chief medical and scientific officer for the American Cancer Society in this third of four-part video series.

The debate is scheduled to run from 9-10:30 p.m. ET. COVID-19 (but not healthcare) is one of the six topics that will be covered.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a Q&A interview between MHE and the emerging leader.

This week, Briana Contreras of Managed Healthcare Executive spoke with Doctors Art Papier and Nada Elbuluk of VisualDx. Art is a practicing dermatologist and associate professor of dermatology and medical informatics at University of Rochester, as well as the CEO of VisualDx. Nada is also a dermatologist in Los Angeles and she is Director of Clinical Impact for VisualDx. The three discussed how providers can leverage health IT to reduce cognitive bias and racial disparities in healthcare.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

Rather than stopping hydroxychloroquine altogether, doses could be reduced and patients monitored if there are signs of retinopathy, say the authors of a commentary in the American Journal of Ophthalmology.

Study shows 12% retained sight for driving and 15% for reading.